For instance, in anti-PD-1 resistant BRAF-mutant melanoma models, concurrent treatment with dabrafenib and trametinib led to significantly enhanced tumor growth inhibition, increased CD8+ cytotoxic and CD4+ helper T cell infiltration, and an upregulation of MHC class I and II molecules [44,45]. This evidence concerns the gene CD8A and neoplasm.